Drug Profile
Research programme: integrase inhibitors - Bioflexis
Alternative Names: BFX 1001; BFX 1002; BFX 1003; BFX 1004; BFX 1005; BFX 1006; BFX 1007; BFX 1008Latest Information Update: 16 Mar 2007
Price :
$50
*
At a glance
- Originator Bioflexis LLC
- Class
- Mechanism of Action Chelating agents; HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 27 Jan 2006 Preclinical trials in HIV infections in USA (unspecified route)